Strategic partnerships ChromaCode has active recent partnerships with Georgia health and the Medical College of Georgia focusing on rapid biomarker testing in non-small cell lung cancer, presenting opportunities to upsell integrated diagnostic workflows, data analytics services, and expanded access programs.

Oncology focus The company has launched an NSCLC assay and partnered with cancer diagnostic labs, indicating a strong signature for oncology-centered molecular diagnostics that can be targeted with additional panels, companion diagnostics collaborations, and clinical deployment services.

Cloud enabled With ChromaCode Cloud 6.1 and a cloud-first analysis platform, there is potential to offer scalable data processing, secure data exchange, and managed analytics services to large life sciences and hospital networks seeking interoperable AI-driven insights.

Funding momentum Having raised substantial funding and a revenue range of 1–10 million, there is runway for strategic collaborations, co-development deals, and patient access programs that leverage their signaling enhancement technology to accelerate diagnostics adoption.

Biotech ecosystem fit Strong pedigree from Illumina, Google X, Luminex, and Caltech combined with a modular test kit approach positions ChromaCode as a partner for instrument manufacturers, CROs, and reference labs seeking cost-effective, high-performance assays and expanded multiplexing capabilities.